MYD88 L265P mutation analysis helps define nodal lymphoplasmacytic lymphoma

Modern Pathology

Volumn 28, Issue 4, 2015, Pages 564-574

  Hamadeh, Fatima ^a   MacNamara, Stephen P ^a   Aguilera, Nadine S ^b   Swerdlow, Steven H ^c   Cook, James R ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF VIRGINIA   (United States)

^c UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN M; PARAPROTEIN; MYD88 PROTEIN, HUMAN; MYELOID DIFFERENTIATION FACTOR 88;

ADULT; AGED; ARTICLE; B CELL LYMPHOMA; BONE MARROW DISEASE; CANCER MORPHOLOGY; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL FEATURE; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DIFFERENTIAL DIAGNOSIS; FEMALE; GENE MUTATION; GENETIC ASSOCIATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LYMPHOCYTOMA; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MUTATIONAL ANALYSIS; MUTATOR GENE; MYD88 GENE; NODAL MARGINAL ZONE LYMPHOMA; PLASMA CELL LEUKEMIA; PRIORITY JOURNAL; SPLENIC MARGINAL ZONE LYMPHOMA; TUMOR DIFFERENTIATION; WALDENSTROEM MACROGLOBULINEMIA; WORLD HEALTH ORGANIZATION; B LYMPHOCYTE; DNA MUTATIONAL ANALYSIS; GENETICS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; LYMPHOMA, B-CELL, MARGINAL ZONE; MUTATION; PATHOLOGY; VERY ELDERLY; WALDENSTROM MACROGLOBULINEMIA;

ADULT; AGED; AGED, 80 AND OVER; B-LYMPHOCYTES; DIAGNOSIS, DIFFERENTIAL; DNA MUTATIONAL ANALYSIS; FEMALE; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; LYMPHOMA, B-CELL, MARGINAL ZONE; MALE; MIDDLE AGED; MUTATION; MYELOID DIFFERENTIATION FACTOR 88; WALDENSTROM MACROGLOBULINEMIA;

EID: 84926519624     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.2014.120     Document Type: Article

References (57)

1. Lin P, Medeiros LJ. Lymphoplasmacytic lymphoma/ waldenstrom macroglobulinemia: an evolving concept. Adv Anat Pathol 2005;12:246-255.
2. Swerdlow SH, Berger F, Pileri SA, et al. Lymphoplasmacytic Lymphoma, In: Swerdlow SH, Campo E, Harris NL, et al. (eds), WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. IARC Press: Lyon; 2008, pp 194-195.
3. Cook JR. Nodal and leukemic small B-cell neoplasms. Mod Pathol 2013;26(Suppl 1):S15-S28.
4. Lin P, Molina TJ, Cook JR, et al. Lymphoplasmacytic lymphoma and other non-marginal zone lymphomas with plasmacytic differentiation. Am J Clin Pathol 2011;136:195-210.
5. Bennett M, Farrer-Brown G, Henry K, et al. Classification of non-Hodgkin's lymphomas. Lancet 1974;304: 405-408.
6. Lukes RJ, Collins RD. Immunologic characterization of human malignant lymphomas. Cancer 1974;34(suppl): 1488-1503.
7. Andriko JA, Swerdlow SH, Aguilera NI, et al. Is lymphoplasmacytic lymphoma/immunocytoma a distinct entity? A clinicopathologic study of 20 cases. Am J Surg Pathol 2001;25:742-751.
8. Sargent RL, Cook JR, Aguilera NI, et al. Fluorescence immunophenotypic and interphase cytogenetic characterization of nodal lymphoplasmacytic lymphoma. Am J Surg Pathol 2008;32:1643-1653.
9. Cook JR, Aguilera NI, Reshmi S, et al. Deletion 6q is not a characteristic marker of nodal lymphoplasmacytic lymphoma. Cancer Genet Cytogenet 2005;162:85-88.
10. Cook JR, Aguilera NI, Reshmi-Skarja S, et al. Lack of PAX5 rearrangements in lymphoplasmacytic lymphomas: reassessing the reported association with t(9;14). Hum Pathol 2004;35:447-454.
11. Treon SP, Xu L, Yang G, et al. MYD88 L265P Somatic Mutation in Waldenström's Macroglobulinemia. N Engl J Med 2012;367:826-833.
12. Jiménez C, Sebastián E, Chillón MC, et al. MYD88 L265P is a marker highly characteristic of, but not restricted to, Waldenström's macroglobulinemia. Leukemia 2013;27:1722-1728.
13. Treon SP, Hunter ZR. A new era for Waldenstrom macroglobulinemia: MYD88 L265P. Blood 2013;121: 4434-4436.
14. Poulain S, Roumier C, Decambron A, et al. MYD88 L265P mutation in Waldenstrom macroglobulinemia. Blood 2013;121:4504-4511.
15. Xu L, Hunter ZR, Yang G, et al. MYD88 L265P in Waldenström macroglobulinemia, immunoglobulin M monoclonal gammopathy, and other B-cell lymphoproliferative disorders using conventional and quantitative allele-specific polymerase chain reaction. Blood 2013;121:2051-2058.
16. Mori N, Ohwashi M, Yoshinaga K, et al. L265P mutation of the MYD88 gene Is frequent in Waldenström's macroglobulinemia and its absence in myeloma. PLoS One 2013;8:e80088.
17. Ondrejka SL, Lin JJ, Warden DW, et al. MYD88 L265P somatic mutation: its usefulness in the differential diagnosis of bone marrow involvement by B-cell lymphoproliferative disorders. Am J Clin Pathol 2013;140:387-394.
18. Swerdlow SH, Campo E, Harris NL, et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. IARC Press: Lyon; 2008, pp 179-269.
19. Ngo VN, Young RM, Schmitz R, et al. Oncogenically active MYD88 mutations in human lymphoma. Nature 2011;470:115-119.
20. Li Z-M, Rinaldi A, Cavalli A, et al. MYD88 somatic mutations in MALT lymphomas. Br J Haematol 2012;158:662-664.
21. Varettoni M, Arcaini L, Zibellini S, et al. Prevalence and clinical significance of the MYD88 (L265P) somatic mutation in Waldenstrom's macroglobulinemia and related lymphoid neoplasms. Blood 2013; 121:2522-2528.
22. Gachard N, Parrens M, Soubeyran I, et al. IGHV gene features and MYD88 L265P mutation separate the three marginal zone lymphoma entities and Waldenström macroglobulinemia/lymphoplasmacytic lymphomas. Leukemia 2013;27:183-189.
23. Landgren O, Staudt L. MYD88 L265P somatic mutation in IgM MGUS. N Engl J Med 2012;367:2255-2256.
24. Wang L, Lawrence MS, Wan Y, et al. SF3B1 and other novel cancer genes in chronic lymphocytic leukemia. N Engl J Med 2011;365:2497-2506.
25. Martnez-Trillos A, Pinyol M, Navarro A, et al. Mutations in the Toll-like receptor/MYD88 pathway in chronic lymphocytic leukemia identify a subset of young patients with favorable outcome. Blood 2014;123:3790-3796.
26. Puente XS, Pinyol M, Quesada V, et al. Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia. Nature 2011;475:101-105.
27. Ho Y, Xu L, Treon SP, et al. MYD88 L265P mutation analysis aids in classifying nodal small B-cell lymphomas. Mod Pathol 2014;27:351A.
28. Carbone A, Gloghini A, Santoro A. In situ follicular lymphoma: pathologic characteristics and diagnostic features. Hematol Oncol 2012;30:1-7.
29. Jegalian AG, Eberle FC, Pack SD, et al. Follicular lymphoma in situ: clinical implications and comparisons with partial involvement by follicular lymphoma. Blood 2011;118:2976-2984.
30. Mamessier E, Broussais-Guillaumot F, Chetaille B, et al. Nature and importance of follicular lymphoma precursors. Haematologica 2014;99:802-810.
31. Xu Y, McKenna RW, Kroft SH. Assessment of CD10 in the diagnosis of small B-cell lymphomas: a multiparameter flow cytometric study. Am J Clin Pathol 2002;117:291-300.
32. Yatabe Y, Suzuki R, Matsuno Y, et al. Morphological spectrum of cyclin D1-positive mantle cell lymphoma: study of 168 cases. Pathol Int 2001;51: 747-761.
33. Traverse-Glehen A, Baseggio L, Bauchu EC, et al. Splenic red pulp lymphoma with numerous basophilic villous lymphocytes: a distinct clinicopathologic and molecular entity? Blood 2008;111:2253-2260.
34. Mollejo M, Algara P, Mateo MS, et al. Splenic small B-cell lymphoma with predominant red pulp involvement: a diffuse variant of splenic marginal zone lymphoma? Histopathology 2002;40:22-30.
35. Piris MA, Foucar K, Mollejo M, et al. Splenic B-cell lymphoma/leukemia, unclassifiable, In: Swerdlow SH, Campo E, Harris NL, et al. (eds), WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. IARC Press: Lyon; 2008, pp 191-193.
36. Arber DA, Rappaport H, Weiss LM. Non-Hodgkin's lymphoproliferative disorders involving the spleen. Mod Pathol. 1997;10:18-32.
37. Lin P, Bueso-Ramos C, Wilson CS, et al. Waldenstrom macroglobulinemia involving extramedullary sites: morphologic and immunophenotypic findings in 44 patients. Am J Surg Pathol. 2003;27:1104-1113.
38. Anelli L, Zagaria A, Minervini A, et al. IgG-lymphoplasmacytic lymphoma following polycythemia vera: JAK2 V617F and MYD88 L265P mutations separated in the same house. Ann Hematol 2014;3:1-9.
39. Manasanch EE, Braylan R, Stetler-Stevenson M, et al. Lack of MYD88 L265P in non-immunoglobulin M lymphoplasmacytic lymphoma. Leuk Lymphoma 2013;55:1402-1403.
40. Cortese D, Sutton L-A, Cahill N, et al. On the way towards a 'CLL prognostic index': focus on TP53, BIRC3, SF3B1, NOTCH1 and MYD88 in a populationbased cohort. Leukemia 2014;28:710-713.
41. Jeromin S, Weissmann S, Haferlach C, et al. SF3B1 mutations correlated to cytogenetics and mutations in NOTCH1, FBXW7, MYD88, XPO1 and TP53 in 1160 untreated CLL patients. Leukemia 2014;28: 108-117.
42. Kyrtsonis MC, Vassilakopoulos TP, Angelopoulou MK, et al. Waldenström's macroglobulinemia: clinical course and prognostic factors in 60 patients. Experience from a single hematology unit. Ann Hematol 2001;80:722-727.
43. Choi J-W, Kim Y, Lee J-H, et al. MYD88 expression and L265P mutation in diffuse large B-cell lymphoma. Hum Pathol 2013;44:1375-1381.
44. Kraan W, Horlings HM, van Keimpema M, et al. High prevalence of oncogenic MYD88 and CD79B mutations in diffuse large B-cell lymphomas presenting at immune-privileged sites. Blood Cancer J 2013;3:e139.
45. Pham-Ledard A, Prochazkova-Carlotti M, Andrique L, et al. Multiple genetic alterations in primary cutaneous large B-cell lymphoma, leg type support a common lymphomagenesis with activated B-cell-like diffuse large B-cell lymphoma. Mod Pathol 2014;27:402-411.
46. Kraan W, van Keimpema M, Horlings HM, et al. High prevalence of oncogenic MYD88 and CD79B mutations in primary testicular diffuse large B-cell lymphoma. Leukemia 2014;28:719-720.
47. Kim Y, Ju H, Kim DH, et al. CD79B and MYD88 mutations in diffuse large B-cell lymphoma. Hum Pathol 2014;45:556-564.
48. Molina TJ, Lin P, Swerdlow SH, et al. Marginal zone lymphomas with plasmacytic differentiation and related disorders. Am J Clin Pathol 2011;136:211-225.
49. Oscier D, Owen R, Johnson S. Splenic marginal zone lymphoma. Blood Rev 2005;19:39-51.
50. Van Huyen JP, Molina T, Delmer A, et al. Splenic marginal zone lymphoma with or without plasmacytic differentiation. Am J Surg Pathol 2000;24:1581-1592.
51. Dufresne SD, Felgar RE, Sargent RL, et al. Defining the borders of splenic marginal zone lymphoma: a multiparameter study. Hum Pathol 2010;41:540-551.
52. Isaacson PG, Piris MA, Berger F, et al. Splenic B-cell marginal zone lymphoma, In: Swerdlow SH, Campo E, Harris NL, et al. (eds), WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. IARC Press: Lyon; 2008, pp 185-187.
53. Berentsen S, Beiske K, Tjnnfjord GE. Primary chronic cold agglutinin disease: an update on pathogenesis, clinical features and therapy. Hematology 2007;12: 361-370.
54. Berentsen S, Ulvestad E, Langholm R, et al. Primary chronic cold agglutinin disease: a population based clinical study of 86 patients. Haematologica 2006; 91:460-466.
55. Randen U, Tren G, Tierens A, et al. Primary cold agglutinin-associated lymphoproliferative disease: a B-cell lymphoma of the bone marrow distinct from lymphoplasmacytic lymphoma. Haematologica 2014; 99:497-504.
56. Bieliauskas S, Tubbs RR, Bacon CM, et al. Gamma heavy-chain disease: defining the spectrum of associated lymphoproliferative disorders through analysis of 13 cases. Am J Surg Pathol 2012;36:534-543.
57. Hamadeh F, MacNamara S, Bacon CM, et al. Gamma heavy chain disease lacks the MYD88 L265P mutation associated with lymphoplasmacytic lymphoma. Haematologica 23 May 2014; e-pub ahead of print.